Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride is a novel small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1, showing IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively (Lin et al., 2018). It inhibits endothelial cell migration and capillary tube formation in vitro in a concentration-dependent manner. Compared to sunitinib, sorafenib, and nintedanib, Anlotinib demonstrates superior anti-angiogenic effects. The compound has favorable pharmacokinetics, including high plasma protein binding and the ability to cross the blood-brain barrier. APExBIO supplies Anlotinib (hydrochloride) (SKU C8688), enabling robust and reproducible tumor angiogenesis research (APExBIO).

Biological Rationale

Tumor angiogenesis is essential for cancer growth and metastasis. Neovasculature supplies nutrients and oxygen to tumors, driven by pro-angiogenic factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), and fibroblast growth factor-2 (FGF-2) (Lin et al., 2018). VEGF predominantly activates VEGFR2 on endothelial cells, initiating downstream signaling cascades, including the ERK pathway. PDGF-BB and FGF-2 activate PDGFRβ and FGFR1, respectively, further modulating angiogenic processes. Targeting these pathways with small-molecule inhibitors is an established strategy in translational cancer research (Prescission 2022).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor (TKI) designed to block angiogenic signaling at multiple nodes. It binds the ATP-binding sites of VEGFR2, PDGFRβ, and FGFR1, inhibiting receptor autophosphorylation and downstream signaling through the ERK pathway. The compound’s IC₅₀ values for VEGFR2 (5.6 ± 1.2 nM), PDGFRβ (8.7 ± 3.4 nM), and FGFR1 (11.7 ± 4.1 nM) were determined in cell-free kinase assays at 25°C, pH 7.4, in the presence of 1 mM ATP (Lin et al., 2018). Anlotinib blocks endothelial cell migration and capillary-like tube formation, as shown in EA.hy 926 cell migration and tube formation assays. The inhibition is concentration-dependent and more pronounced than with sunitinib, sorafenib, or nintedanib under matched conditions (APExBIO Q&A).

Evidence & Benchmarks

• Anlotinib hydrochloride inhibits VEGF/PDGF-BB/FGF-2-induced endothelial cell migration in vitro, measured by wound healing and chamber migration assays (Lin et al., 2018, DOI).
• IC₅₀ for VEGFR2: 5.6 ± 1.2 nM; PDGFRβ: 8.7 ± 3.4 nM; FGFR1: 11.7 ± 4.1 nM, determined in kinase activity assays (DOI).
• Suppresses capillary-like tube formation by EA.hy 926 endothelial cells in Matrigel assays at concentrations as low as 10 nM (Lin et al., 2018, DOI).
• Demonstrates superior inhibition of angiogenesis compared with sunitinib, sorafenib, and nintedanib in matched in vitro and in vivo models (DOI).
• Displays rapid oral absorption with bioavailability ranging from 28% to 58% in rats and 41% to 77% in dogs; high plasma protein binding (93% in humans) (DOI).
• Minimal organ or genetic toxicity observed in 14-day oral administration studies (LD₅₀: 1735.9 mg/kg) (DOI).

This article extends the mechanistic perspective from Redefining Tumor Angiogenesis Inhibition by focusing on quantitative assay parameters and comparative inhibition profiles for Anlotinib.
It also updates the practical assay guidance found in Optimizing Angiogenesis Assays with Anlotinib (hydrochloride) with new pharmacokinetic and selectivity data.
For an expanded pharmacology context, see Unraveling Multi-Target Angiogenesis Inhibition; here, we prioritize experimental design and reproducibility benchmarks.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is used in cellular and in vivo assays for anti-angiogenic research. Typical applications include:

• Inhibition of endothelial cell migration (e.g., EA.hy 926 line).
• Capillary-like tube formation assays on Matrigel or collagen.
• Analysis of ERK signaling pathway inhibition following VEGFR2/PDGFRβ/FGFR1 blockade.
• Translational cancer models studying tumor angiogenesis and metastasis.

Common Pitfalls or Misconceptions

• Anlotinib is not suitable for diagnostic or therapeutic use in humans; it is strictly for scientific research (APExBIO).
• Not a pan-kinase inhibitor: Specificity is limited to select tyrosine kinases (VEGFR2, PDGFRβ, FGFR1), not all kinases.
• Does not block angiogenesis in every tumor type equally: Efficacy is context-dependent and should be validated per model.
• Cellular toxicity at high doses: While LD₅₀ is high, off-target effects may arise above recommended concentrations.
• Results may not directly translate to in vivo efficacy in clinical settings: Animal and cell-based data are not substitutes for clinical results.

Workflow Integration & Parameters

The Anlotinib (hydrochloride) C8688 kit from APExBIO is supplied at >98% purity and is recommended for storage at –20°C. For cellular assays, concentrations typically range from 1 nM to 1 μM, with DMSO as solvent (final DMSO ≤ 0.1%). Migration and tube formation assays use EA.hy 926 or HUVEC cells, seeded at 1–2 × 10⁵ cells/well, and incubated with Anlotinib for 8–24 hours at 37°C, 5% CO₂. For ERK pathway analysis, cells are lysed post-treatment and analyzed by immunoblot or ELISA.

Anlotinib’s favorable membrane permeability and rapid absorption enable oral administration in animal studies. Metabolism is primarily via CYP3A, yielding hydroxylated and dealkylated metabolites (Lin et al., 2018). The compound’s distribution covers lung, liver, kidney, heart, and tumor tissue, and it can cross the blood-brain barrier.

Conclusion & Outlook

Anlotinib hydrochloride is a validated, multi-target tyrosine kinase inhibitor with superior selectivity for VEGFR2, PDGFRβ, and FGFR1. It is well-suited for research on anti-angiogenic mechanisms, endothelial cell migration, and capillary tube formation. Supplied by APExBIO (SKU C8688), it supports reproducible, high-fidelity cancer research workflows. As new clinical and preclinical data emerge, Anlotinib will remain a benchmark tool for dissecting angiogenic signaling and informing translational research strategies (Lin et al., 2018).